Ignite Creation Date:
2024-10-26 @ 3:37 PM
Last Modification Date:
2024-10-26 @ 3:37 PM
Study NCT ID:
NCT06550947
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-08-09
Brief Title:
ALDOA Expression in Bladder Urothelial Carcinoma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Immunohistochemical Expression and Prognostic Significance of ALDOA in Bladder Urothelial Carcinoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
1 Study the immunohistochemical expression of ALDOA in bladder urothelial cancer
2 Correlate between ALDOA expression in specimens and different cilnicopathological factors
3 Correlate between ALDOA expression and urothelial cancer prognosis and survival
2 Correlate between ALDOA expression in specimens and different cilnicopathological factors
3 Correlate between ALDOA expression and urothelial cancer prognosis and survival
Detailed Description:
Bladder cancer is the 7th most prevalent malignancy and the 13th cause of cancer related death worldwide1 In Egypt its the third most common tumor2
The most common histologic subtype of bladder cancer is urothelial carcinoma3 Bladder cancer is divided according to absence or presence of muscle invasion into non-muscle invasive bladder cancer and muscle invasive bladder cancer 3
Despite the advance in diagnosis and development of therapeutic options of urothelial cancer the recurrence and progression rate remains high4
The conventional histopathological evaluation of urothelial cancer is vital for diagnosis and prediction of patients prognosis However it doesnt fully reflect the biological behavior of the tumor or the clinical outcome of the patient5
Under hypoxic conditions cancer cells produce ATP by glycolysis which provide energy for tumor proliferation and dissemination67 Glycolytic enzymes are abnormally activated in cancer cells89 Thus several studies have identified glycolytic enzymes or related metabolic pathways as potential drug targets One of the typical glycolytic enzymes is Aldolase A ALDOA 6 which is the most abundant glycolytic enzyme detected in tumors10
Several studies have identified ALDOA as an oncogene in different types of malignancy 6810-12 The oncogenic potential of ALDOA contributed to its ability to stimulate DNA synthesis and accelerate S phase in tumor cell cycle6-8
In addition studies have shown that ALDOA promotes tumor cell invasion by negative regulation of E-cadherin and by activation of MAPK AKT and EGFR signaling pathways71113
Thus increased expression of ALDOA in tumor predicts a bad prognosis and poor survival of patients13-15
The most common histologic subtype of bladder cancer is urothelial carcinoma3 Bladder cancer is divided according to absence or presence of muscle invasion into non-muscle invasive bladder cancer and muscle invasive bladder cancer 3
Despite the advance in diagnosis and development of therapeutic options of urothelial cancer the recurrence and progression rate remains high4
The conventional histopathological evaluation of urothelial cancer is vital for diagnosis and prediction of patients prognosis However it doesnt fully reflect the biological behavior of the tumor or the clinical outcome of the patient5
Under hypoxic conditions cancer cells produce ATP by glycolysis which provide energy for tumor proliferation and dissemination67 Glycolytic enzymes are abnormally activated in cancer cells89 Thus several studies have identified glycolytic enzymes or related metabolic pathways as potential drug targets One of the typical glycolytic enzymes is Aldolase A ALDOA 6 which is the most abundant glycolytic enzyme detected in tumors10
Several studies have identified ALDOA as an oncogene in different types of malignancy 6810-12 The oncogenic potential of ALDOA contributed to its ability to stimulate DNA synthesis and accelerate S phase in tumor cell cycle6-8
In addition studies have shown that ALDOA promotes tumor cell invasion by negative regulation of E-cadherin and by activation of MAPK AKT and EGFR signaling pathways71113
Thus increased expression of ALDOA in tumor predicts a bad prognosis and poor survival of patients13-15
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None